• Home
  • The Quivive Team
  • For Investors
  • News & Events
  • More
    • Home
    • The Quivive Team
    • For Investors
    • News & Events
  • Home
  • The Quivive Team
  • For Investors
  • News & Events

Quivive's Executive Team

John Hsu, MD, CEO Founder

Peter Rix, DABT, Chief Scientific Officer

Peter Rix, DABT, Chief Scientific Officer

In addition to his 28 years as a practicing anesthesiologist and pain management specialist, Dr Hsu is a serial entrepreneur who has founded companies in the areas of medical devices and healthcare management software and consulting.   

https://www.linkedin.com/in/john-hsu-300a8b2a
 

Peter Rix, DABT, Chief Scientific Officer

Peter Rix, DABT, Chief Scientific Officer

Peter Rix, DABT, Chief Scientific Officer

A drug development expert with 26 years of experience in pharmaceutical R&D, Peter has led or supported the development of six FDA-approved products and been involved in two major exits: Aragon to Janssen ($1B) and Saragon to Genetech-Roche ($1.75B)

https://www.linkedin.com/in/peter-rix-40b3703 

Peter Weinstein, PhD, JD, General Counsel

Gary Seelhorst, MBA, Senior VP Business Development

Gary Seelhorst, MBA, Senior VP Business Development

A highly experienced patent litigator and former USPTO reviewer and attorney, Dr. Weinstein  manages all aspects of intellectual property, transactions and corporate law. He also has significant pharma experience with support of two marketed products.

https://www.linkedin.com/in/peter-weinstein-4402389
 

Gary Seelhorst, MBA, Senior VP Business Development

Gary Seelhorst, MBA, Senior VP Business Development

Gary Seelhorst, MBA, Senior VP Business Development

Gary has 23 years of clinical and corporate development experience with both large-cap and start-up pharmaceutical and medical device ventures, including marketing, in-licensing, strategic partnerships and M&A transactions.

https://www.linkedin.com/in/gary-seelhorst-1a798b1
 

Advisory Board and Key Consultants

Robert Rappaport, MD

Former FDA Director (CDER Division of Anesthesia, Analgesia and Addiction Products)

Brian Harvey, MD, PhD

Former FDA Director (CDER Division of Gastroenterology Products  Office of New Drugs)

Lynn Webster, MD

Clinical pain specialist, key opinion leader and past president of the American Academy of Pain Medicine

Lacarya Scott, MS, MBA

Pharmaceutical and medical device corporate strategist, M&A and investment

Sherie Hsieh, BS

Clinical toxicologist, strategist and marketing executive

Andrew Parkinson, PhD

Recognized authority and key opinion leader in drug metabolism, safety and disposition

Drazen Ostovic, PhD

Expert in formulation and combo drug development with extensive Pharma experience

Joseph Cotten, MD, PhD

Clinical anesthesiologist, assistant professor Harvard Medical School, Mass General

Thomas Studebaker, MBA

Business development expert with numerous pharmaceutical and medical device start-ups

Pharmaceutical Development Partners

Camargo Pharmaceutical Services

Industry leader 505(b)(2) submissions to FDA with extensive opioid and analgesic experience

PRA Health Sciences

Industry leader in clinical assessments of respiratory safety and abuse deterrence of opioids

Catalent Pharma Solutions

Worldwide leader in development and commercialization of  pharmaceutical drug products


Copyright © 2022 Quivive Pharma, inc - All Rights Reserved.